Content uploaded by Hani Salim
Author content
All content in this area was uploaded by Hani Salim on Sep 29, 2022
Content may be subject to copyright.
Available via license: CC BY 4.0
Content may be subject to copyright.
VIEWPOINTS
PAPERS
www.jogh.org • doi: 10.7189/jogh.12.04052 1 2022 • Vol. 12 • 04052
Peige Song1*, Davies Adeloye2*,
Hani Salim2,3, Jhonathan PR Dos
Santos4, Harry Campbell2, Aziz
Sheikh2, Igor Rudan2
1
School of Public Health and Women’s
Hospital, Zhejiang University School
of Medicine, Hangzhou, China
2
Usher Institute, University of
Edinburgh, Edinburgh, UK
3
Department of Family Medicine,
Faculty of Medicine and Health
Sciences, University Putra Malaysia,
Serdang, Malaysia
4
Cornell University, Ithaca, New York,
United States
*These authors contributed equally
Correspondence to:
Professor Igor Rudan, FRSE
Centre for Global Health
Usher Institute
The University of Edinburgh
Edinburgh
UK
Igor.Rudan@ed.ac.uk
Global, regional, and national prevalence of
asthma in 2019: a systematic analysis and
modelling study
Electronic supplementary material:
The online version of this article contains supplementary material.
Background Asthma has a significant impact on people of all ages, particularly chil-
dren. A lack of universally accepted case definition and confirmatory tests and a poor
understanding of major risks interfere with a global response. We aimed to provide
global estimates of asthma prevalence and cases in 2019 across four main epidemio-
logical case definitions – current wheezing, ever wheezing, current asthma, and ever
asthma. We further investigated major associated factors to determine regional and
national distributions of prevalence and cases for current wheezing and ever asthma.
Methods We identified relevant population-based studies published between Janu-
ary 1, 1990, and December 31, 2019. Using a multilevel multivariable mixed-effects
meta-regression model, we assessed the age- and sex-adjusted associations of asth-
ma with study-level variables, including year, setting, region and socio-demograph-
ic index (SDI). Using a random-effects meta-analysis, we then identified risk factors
for current wheezing and asthma. From a “risk factor-based model”, which includ-
ed current smoking, and biomass exposure for current wheezing, and rural setting,
current smoking, biomass exposure, and SDI for ever asthma, we estimated case
numbers and prevalence across regions and 201 countries and territories in 2019.
Results 220 population-based studies conducted in 88 countries were retained. In
2019, the global prevalence estimates of asthma in people aged 5-69 years by various
definitions, namely current wheezing, ever wheezing, current asthma, and ever asth-
ma were 11.5% (95% confidence interval (CI) = 9.1-14.3), 17.9% (95% CI = 14.2-
22.3), 5.4% (95% CI = 3.2-9.0) and 9.8% (95% CI = 7.8-12.2), respectively. These
translated to 754.6 million (95% CI = 599. 7-943.4), 1181.3 million (95% CI = 938.0-
1,471.0), 357.4 million (95% CI = 213.0-590.8), 645.2 million (95% CI = 513.1-
806.2) cases, respectively. The overall prevalence of current wheezing among people
aged 5-69 years was the highest in the African Region at 13.2% (95% CI = 10.5-16.5),
and the lowest in the Americas Region at 10.0% (95% CI = 8.0-12.5). For ever asth-
ma, the estimated prevalence in those aged 5-69 years was also the highest in the
African Region at 11.3% (95% CI = 9.0-14.1), but the lowest in South-East Asia Re-
gion (8.8, 95% CI = 7.0-11.0).
Conclusions Although varying approaches to case identification in different set-
tings make epidemiological estimates of asthma very difficult, this analysis reaffirms
asthma as a common global respiratory condition before the COVID-19 pandemic
in 2019, with higher prevalence than previously reported in many world settings.
Cite as: Song P, Adeloye D, Salim H, Dos Santos JPR, Campbell H, Sheikh
A, Rudan I. Global, regional, and national prevalence of asthma in 2019: a
systematic analysis and modelling study. J Glob Health 2022;12:04052.
© 2022 The Author(s)
JoGH © 2022 ISoGH
Song et al.
VIEWPOINTS
PAPERS
2022 • Vol. 12 • 04052 2 www.jogh.org • doi: 10.7189/jogh.12.04052
Asthma is a major chronic respiratory disease substantially affecting the quality of life of people of all ages,
particularly children who experience more years of poorer life quality compared to adults [1]. In 2019, Global
Burden of Disease (GBD) collaborators estimated that over 260 million people globally had poorly controlled
asthma (diagnosed asthma with wheezing within past 12 months) [1], with a high count of disabilities and
premature deaths across many low- and middle-income countries (LMICs) [1,2].
To date, there is no universally accepted case definition or a combination of tests that are confirmatory for asth-
ma. The varying approaches to defining asthma reflect a different understanding of the aetiology and inform
epidemiological estimates across settings. Based on the responses to questions relating to self-reported diag-
nosis and respiratory symptoms over a set period, four main definitions have been reported, including “cur-
rent wheezing”, “ever wheezing”, “newly-diagnosed asthma”, and “ever asthma”. According to reports from
major international respiratory groups, including the International Study of Asthma and Allergies in Child-
hood (ISAAC), the Global Asthma Network (GAN), and the European Community Respiratory Health Survey
(ECRHS), “current wheezing” (within the past 12 months) was found to be a sensitive epidemiological defi-
nition for active asthma, while the “ever-diagnosed asthma” definition was specific for lifetime asthma [3,4].
The challenges of combining prevalence data across asthma definitions, with inconsistencies in many settings,
have been previously highlighted [4-6]. Guided by the above definitions, this study looks to improve the un-
derstanding of the global epidemiology of asthma, necessary to inform policy, research, and practice. First, we
aimed to provide the global estimates of current wheezing, ever wheezing, current asthma, and ever asthma
prevalence and cases in 2019, before the COVID-19 pandemic. We then investigated major associated factors
of current wheezing and ever asthma across high-income countries (HICs) and LMICs to explore the regional
and national distributions of asthma prevalence and cases in 2019.
METHODS
This study was conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Me-
ta-Analyses (PRISMA) reporting guidelines [7].
Search strategy
We combined various Medical Subject Headings (MeSH) terms on the epidemiology of asthma separately in
four bibliographic databases (CINAHL, Embase, Global Health, and MEDLINE) to identify relevant popula-
tion-based studies published between January 1, 1990, and December 31, 2019. Additional searches were
conducted on Google Scholar. The reference lists of included articles and relevant systematic reviews on the
epidemiology of asthma were further hand-searched. No language or geographical restrictions were applied.
Full search strategies are provided in Table S1 in the Online Supplementary Document.
Review and data extraction
Studies were included if they were conducted in the general population and reported the asthma prevalence
or associated factors (see Box 1 for eligibility criteria).
Inclusion criteria
1. Population-based studies that reported the prevalence and/or associated factors (adjusted odds ratio) of asthma in the general population;
2. Studies in 1 that defined asthma on the basis of wheezing symptoms or asthma diagnosis (ie, a self-reported history of wheeze symp-
toms in the preceding 12 months (current wheezing”) or asthma diagnosis by a physician (“ever asthma”));
3. Studies in 2 that employed a protocol or questionnaire that had been validated and/or implemented in large-scale epidemiology stud-
ies; and
4. Studies in 3 that were published between January 1, 1990 and December 31, 2019.
Exclusion criteria
1. Studies that were not population-based, that were derived from hospital or administrative data, or that were conducted in a specific
population group which was not representative of the general population;
2. Studies that did not provide the prevalence and associated factors of asthma;
3. Studies where study design and case ascertainment of asthma were unclear; and
4. Reviews, case reports, opinion-based articles, and viewpoints.
Box 1.
Eligibility criteria
Global, regional and naonal prevalence of asthma in 2019
VIEWPOINTS
PAPERS
www.jogh.org • doi: 10.7189/jogh.12.04052 3 2022 • Vol. 12 • 04052
Title and abstract screening, followed by a full-text review and data extraction were conducted independently
by DA, HS, and PS. Discrepancies were resolved by consensus. We extracted data on first author, year of pub-
lication, study location, country, study design, sampling method, study setting, year of investigation, asthma
case definition, protocol employed, sample size, proportion of female participants, average (or median) age of
participants, number of asthma cases, and prevalence. The year-specific socio-demographic index (SDI) for
each country was also extracted [8]. The geographic region was categorized according to the World Health
Organization (WHO) and included the African Region (AFR), the Region of the Americas (AMR), the South-
East Asia Region (SEAR), the European Region (EUR), the Eastern Mediterranean Region (EMR) and the West-
ern Pacific Region (WPR). The socio-economic region was categorized by the World Bank (WB) as HICs and
LMICs. More details are provided in Table S2 in the Online Supplementary Document.
When provided, stratified prevalence data were extracted by age group, sex, or setting. For studies with cen-
sored age group band, we assumed the same interval as reported for the other age groups within the same
study. Associated factors (and definitions) and the corresponding fully-adjusted odds ratios (ORs) were ex-
tracted from articles that estimated the risk of asthma using multivariable logistic regressions.
Statistical analysis
To reduce heterogeneity, we sorted data and estimates by: 1) current wheezing: wheezing in the past 12 months;
and 2) ever wheezing: ever wheezing across the lifespan; 3) current asthma: newly-diagnosed asthma in the
past 12 months; 4) ever asthma: ever diagnosed asthma across lifespan. The detailed analytic approach is de-
scribed in Figure 1 as well as Appendix 2 in the Online Supplementary Document.
Figure 1.
Step-wise approach to modelling the global prevalence of asthma. HICs – high-income countries, LMICs – low- and middle-in-
come countries, WHO – World Health Organization, AFR – African Region, AMR – Region of the Americas, SEAR – South-East Asia
Re-gion, EUR – European Region, EMR – Eastern Mediterranean Region, WPR – Western Pacific Region.
Song et al.
VIEWPOINTS
PAPERS
2022 • Vol. 12 • 04052 4www.jogh.org • doi: 10.7189/jogh.12.04052
Modelling the global prevalence of asthma
To accommodate for the hierarchical data structure, a multilevel multivariable mixed-effects meta-regression
model was fitted to account for the uncertainty of reported prevalence estimates and their clustering and re-
lations to various factors. A restricted cubic spline basis for age was used to model the prevalence of asthma
as a function of age. Due to limited data sources at young (<5 years) and older ages (≥70 years), we restricted
estimates to 5-69 years. Modelling was separately conducted for HICs and LMICs and details are described in
Table S4 in the Online Supplementary Document.
Estimation of the global numbers of people with asthma in 2019
Based on the estimated age- and sex-specific prevalence of current wheezing, ever wheezing, current asthma
and ever asthma in HICs and LMICs in 2019, we generated the numbers of people affected by current wheez-
ing, ever wheezing, current asthma, and ever asthma respectively, by multiplying the age- and sex-specific
de-facto population in 2019, as reported by the United Nations Population Division (UNPD) [9].
Estimation of the regional and national numbers of people with asthma in 2019
To account for economics and geography simultaneously, we purposely classified the world into ten WB-WHO
regions. We estimated the regional cases of current wheezing and ever asthma using a “risk factor-based model”.
Associated factors assessed in at least three individual studies were included for a random-effects (DerSimonian
and Laird method) meta-analysis [10], based on which two major associated factors, namely current smoking
and biomass exposure, were included in the “risk factor-based model” for current wheezing. Four associated
factors, including rural setting, current smoking and biomass exposure and SDI were selected for ever asthma.
Using the same “risk factor-based model” approach when distributing the global cases of current wheezing and
ever asthma, we estimated the number of affected people for 201 countries and territories in 2019.
All analyses were conducted with STATA version 14.0 (STATA Corporation, College Station, TX, USA) and
R version 3.3.0 (R Foundation for Statistical Computing, Vienna, Austria) using the “metafor” (version 1.9-7)
package.
RESULTS
From 14 422 eligible records after removing duplicates, 523 full texts were assessed. Following the applica-
tion of the eligibility criteria, 220 population-based articles across 88 countries reporting the prevalence and/
or associated factors of asthma were retained. Details of study selection process are presented in Figure 2 and
the contribution of data sources across world regions is provided in Figure S1 in the Online Supplementa-
ry Document. The prevalence of current wheezing, ever wheezing, current asthma and ever asthma, by age
and sex group, based on contributing data points from included articles are shown in Figure S2 in the Online
Supplementary Document. Characteristics and references of all included studies are listed in Tables S5-S6 in
the Online Supplementary Document.
The estimated prevalence of current wheezing, ever wheezing, current asthma, and ever asthma by age in HICs
and LMICs among people aged 5-69 years in 2019 is shown in Table 1 and Figure S3 in the Online Supple-
mentary Document. The prevalence was consistently higher in HICs than in LMICs across the whole age span
of 5-69 years, and the disparity was pronounced for current wheezing and ever asthma- the most sensitive and
most specific definitions of asthma.
The prevalence estimates of current wheezing and ever wheezing both peaked at the ages of 10-14 years. For
current wheezing, the prevalence increased from 11.77% (95% CI = 9.43-14.58) in children aged 5-9 years
to 12.43% (95% CI = 9.97-15.38) in those aged 10-14 years, and then slowly decreased to 11.04% (95%
CI = 8.66-13.98) among elderly persons aged 65-69 years. In 2019, the overall prevalence of current wheez-
ing was 11.45% (95% CI = 9.10-14.32) worldwide, and was slightly higher in HICs (12.14%, 95% CI = 9.76-
15.01) than in LMICs (11.32%, 95% CI = 8.98-14.19). For ever wheezing, the prevalence estimates increased
from 23.35% (95% CI = 18.91-28.46) in children aged 5-9 years to 25.41% (95% CI = 20.68-30.80) in chil-
dren aged 10-14 years, then decreased to 14.30% (95% CI = 11.19-18.10) in people aged 30-34 years, but then
started to gradually increase to 19.12% (95% CI = 15.00-24.06) in those aged 65-69 years. In 2019, the prev-
alence of ever wheezing was 17.93% (95% CI = 14.24-22.32) worldwide, and it was higher in HICs (19.06%,
95% CI = 15.02-23.87) than in LMICs (17.72%, 95% CI = 14.09-22.04).
Global, regional and naonal prevalence of asthma in 2019
VIEWPOINTS
PAPERS
www.jogh.org • doi: 10.7189/jogh.12.04052 5 2022 • Vol. 12 • 04052
The prevalence of current asthma and ever asthma was the highest in younger children aged 5-9 years. For cur-
rent asthma, the prevalence was 13.41% (95% CI = 8.14-21.41) in children aged 5-9 years and 10.95% (95%
CI = 6.59-17.75) in those aged 10-14 years. Thereafter, the prevalence continuously decreased to 2.96% (95%
CI = 1.77-4.95) in the elderly aged 65-69 years. In 2019, the prevalence of current asthma was 5.42% (95%
CI = 3.23-8.97) globally and marginally higher in LMICs (5.43%, 95% CI = 3.11-9.25) than in HICs (5.39%,
95% CI = 3.89-7.42). Similarly, the prevalence of ever asthma peaked at 17.79% (95% CI = 14.36-21.82) in
children aged 5-9 years and then decreased to 6.85% (95% CI = 5.39-8.67) in people aged 45-49 years, only
to gradually increase to 8.05% (95% CI = 6.36-10.15) in persons aged 65-69 years. In 2019, the prevalence of
ever asthma was 9.79% (95% CI = 7.79-12.24) globally and was much higher in HICs (13.39%, 95% CI = 10.75-
16.54) than in LMICs (9.13%, 95% CI = 7.24-11.44).
Global cases of current wheezing, ever wheezing, current asthma and ever asthma
in 2019
By applying the global demographic data, we estimated that there were 754.6 million aged 5-69 years (95%
CI = 599. 7-943.4) with current wheezing, 1181.3 million (95% CI = 938.0-1471.0) with ever wheezing, 357.4
million (95% CI = 213.0-590.8) with current asthma, and 645.2 million (95% CI = 513.1-806.2) with ever asth-
ma in 2019. More than four-fifths of people with current wheezing (83.5%), ever wheezing (83.4%), and cur-
rent asthma (84.5%) were living in LMICs, while 78.7% of people that had ever been diagnosed with asthma
were in LMICs (see Table S7 and Figure S3 in the Online Supplementary Document).
Figure 2.
PRISMA flow diagram of selection of studies.
Song et al.
VIEWPOINTS
PAPERS
2022 • Vol. 12 • 04052 6www.jogh.org • doi: 10.7189/jogh.12.04052
Table 1.
Estimated prevalence of current wheezing, ever wheezing, current asthma, and ever asthma in HICs, LMICs and worldwide in
2019, by age group and sex
Age
group
Male Female Overall
HIC LMIC Worldwide HIC LMIC Worldwide HIC LMIC Worldwide
Current wheezing (%, 95% CI)
5-9 y 13.17 12.17 12.28 12.04 11.12 11.22 12.62 11.66 11.77
(10.72-16.07) (9.75-15.10) (9.85-15.20) (9.78-14.74) (8.88-13.83) (8.98-13.93) (10.26-15.42) (9.33-14.48) (9.43-14.58)
10-14 y 13.89 12.85 12.96 12.71 11.74 11.85 13.31 12.31 12.43
(11.32-16.93) (10.30-15.91) (10.41-16.03) (10.33-15.54) (9.39-14.59) (9.50-14.70) (10.84-16.25) (9.86-15.27) (9.97-15.38)
15-19 y 13.36 12.35 12.47 12.22 11.28 11.39 12.80 11.83 11.95
(10.88-16.31) (9.89-15.32) (10.00-15.43) (9.92-14.96) (9.01-14.04) (9.12-14.14) (10.41-15.65) (9.47-14.70) (9.58-14.81)
20-24 y 12.93 11.95 12.07 11.82 10.91 11.03 12.39 11.44 11.57
(10.46-15.88) (9.51-14.91) (9.63-15.03) (9.54-14.56) (8.66-13.66) (8.77-13.77) (10.01-15.24) (9.10-14.30) (9.21-14.42)
25-29 y 12.67 11.70 11.84 11.58 10.69 10.81 12.15 11.21 11.34
(10.19-15.64) (9.27-14.68) (9.40-14.82) (9.29-14.33) (8.44-13.44) (8.56-13.56) (9.76-15.02) (8.87-14.07) (8.99-14.21)
30-34 y 12.53 11.58 11.71 11.45 10.57 10.69 12.01 11.08 11.21
(10.06-15.50) (9.15-14.54) (9.28-14.68) (9.17-14.20) (8.33-13.31) (8.45-13.44) (9.64-14.88) (8.75-13.94) (8.88-14.07)
35-39 y 12.47 11.52 11.67 11.39 10.51 10.65 11.94 11.02 11.17
(10.01-15.42) (9.10-14.47) (9.25-14.62) (9.13-14.13) (8.29-13.25) (8.42-13.39) (9.58-14.79) (8.70-13.86) (8.84-14.01)
40-44 y 12.43 11.48 11.65 11.36 10.48 10.63 11.91 10.99 11.15
(9.99-15.37) (9.08-14.42) (9.24-14.59) (9.10-14.09) (8.27-13.21) (8.41-13.36) (9.56-14.74) (8.68-13.82) (8.83-13.98)
45-49 y 12.40 11.45 11.63 11.33 10.46 10.61 11.88 10.96 11.12
(9.96-15.34) (9.05-14.39) (9.22-14.57) (9.08-14.06) (8.24-13.18) (8.39-13.34) (9.53-14.71) (8.65-13.79) (8.81-13.96)
50-54 y 12.37 11.42 11.61 11.30 10.43 10.59 11.84 10.92 11.10
(9.92-15.32) (9.01-14.38) (9.19-14.56) (9.04-14.04) (8.21-13.16) (8.37-13.33) (9.48-14.69) (8.61-13.77) (8.78-13.94)
55-59 y 12.34 11.39 11.60 11.27 10.40 10.59 11.80 10.89 11.09
(9.87-15.31) (8.97-14.37) (9.17-14.57) (9.00-14.03) (8.17-13.15) (8.35-13.34) (9.43-14.67) (8.57-13.76) (8.75-13.95)
60-64 y 12.31 11.36 11.59 11.24 10.37 10.58 11.76 10.86 11.07
(9.82-15.32) (8.92-14.37) (9.13-14.60) (8.94-14.04) (8.12-13.16) (8.32-13.37) (9.37-14.67) (8.51-13.75) (8.72-13.97)
65-69 y 12.27 11.33 11.57 11.21 10.35 10.56 11.72 10.82 11.04
(9.75-15.34) (8.86-14.39) (9.09-14.62) (8.89-14.05) (8.07-13.17) (8.27-13.39) (9.30-14.67) (8.45-13.75) (8.66-13.98)
Overall
(5-69 y)
12.68 11.84 11.97 11.59 10.80 10.92 12.14 11.32 11.45
(10.21-15.65) (9.40-14.81) (9.52-14.94) (9.30-14.34) (8.55-13.55) (8.66-13.67) (9.76-15.01) (8.98-14.19) (9.10-14.32)
Ever wheezing (%, 95% CI)
5-9 y 26.51 24.19 24.44 24.11 21.95 22.18 25.34 23.11 23.35
(21.45-32.26) (19.65-29.40) (19.84-29.71) (19.40-29.56) (17.73-26.84) (17.91-27.14) (20.45-30.94) (18.72-28.17) (18.91-28.46)
10-14 y 28.73 26.29 26.56 26.21 23.91 24.17 27.50 25.14 25.41
(23.39-34.74) (21.46-31.77) (21.68-32.10) (21.20-31.92) (19.40-29.09) (19.61-29.41) (22.32-33.37) (20.47-30.48) (20.68-30.8)
15-19 y 22.48 20.42 20.66 20.35 18.44 18.66 21.44 19.46 19.69
(17.99-27.71) (16.41-25.11) (16.59-25.41) (16.19-25.25) (14.75-22.80) (14.92-23.09) (17.11-26.51) (15.61-24.00) (15.79-24.29)
20-24 y 18.71 16.92 17.15 16.86 15.21 15.42 17.81 16.09 16.31
(14.76-23.43) (13.42-21.11) (13.59-21.40) (13.24-21.23) (12.02-19.07) (12.17-19.35) (14.02-22.36) (12.74-20.12) (12.91-20.41)
25-29 y 16.95 15.30 15.53 15.24 13.73 13.94 16.13 14.53 14.76
(13.26-21.42) (12.04-19.25) (12.21-19.56) (11.87-19.36) (10.76-17.35) (10.91-17.63) (12.59-20.44) (11.42-18.33) (11.58-18.62)
30-34 y 16.44 14.83 15.06 14.77 13.30 13.51 15.64 14.08 14.30
(12.82-20.84) (11.63-18.71) (11.81-19.03) (11.47-18.83) (10.40-16.86) (10.55-17.14) (12.17-19.88) (11.03-17.8) (11.19-18.10)
35-39 y 16.71 15.08 15.34 15.02 13.53 13.76 15.89 14.31 14.57
(13.04-21.17) (11.84-19.01) (12.03-19.37) (11.67-19.13) (10.58-17.14) (10.75-17.45) (12.38-20.18) (11.22-18.09) (11.40-18.42)
40-44 y 17.40 15.71 16.01 15.65 14.11 14.37 16.55 14.92 15.20
(13.61-21.98) (12.36-19.77) (12.58-20.16) (12.19-19.89) (11.05-17.83) (11.25-18.19) (12.91-20.96) (11.71-18.81) (11.92-19.19)
45-49 y 18.19 16.44 16.76 16.38 14.78 15.06 17.30 15.61 15.92
(14.26-22.93) (12.96-20.65) (13.20-21.06) (12.78-20.77) (11.59-18.65) (11.81-19.03) (13.53-21.87) (12.28-19.65) (12.51-20.05)
50-54 y 19.01 17.20 17.55 17.14 15.47 15.79 18.09 16.33 16.67
(14.92-23.92) (13.57-21.57) (13.83-22.02) (13.38-21.69) (12.15-19.50) (12.38-19.92) (14.16-22.82) (12.85-20.53) (13.10-20.97)
55-59 y 19.86 17.99 18.39 17.92 16.19 16.56 18.89 17.08 17.47
(15.59-24.96) (14.19-22.54) (14.49-23.06) (14.00-22.66) (12.71-20.40) (12.99-20.89) (14.79-23.81) (13.44-21.46) (13.73-21.97)
60-64 y 20.74 18.8 19.26 18.73 16.94 17.37 19.71 17.85 18.29
(16.28-26.04) (14.82-23.56) (15.17-24.15) (14.62-23.68) (13.29-21.35) (13.60-21.90) (15.43-24.84) (14.03-22.43) (14.37-23.00)
65-69 y 21.64 19.64 20.14 19.57 17.72 18.18 20.56 18.64 19.12
(16.97-27.18) (15.46-24.62) (15.84-25.26) (15.26-24.74) (13.88-22.35) (14.22-22.95) (16.08-25.91) (14.63-23.44) (15.00-24.06)
Overall
(5-69 y)
19.99 18.64 18.85 18.09 16.76 16.97 19.06 17.72 17.93
(15.80-24.97) (14.86-23.13) (15.01-23.41) (14.22-22.73) (13.30-20.92) (13.44-21.20) (15.02-23.87) (14.09-22.04) (14.24-22.32)
Global, regional and naonal prevalence of asthma in 2019
VIEWPOINTS
PAPERS
www.jogh.org • doi: 10.7189/jogh.12.04052 7 2022 • Vol. 12 • 04052
Age
group
Male Female Overall
HIC LMIC Worldwide HIC LMIC Worldwide HIC LMIC Worldwide
Current asthma (%, 95% CI)
5-9 y 15.24 13.58 13.76 14.46 12.87 13.04 14.86 13.24 13.41
(11.34-20.19) (8.00-22.12) (8.36-21.91) (10.73-19.20) (7.56-21.07) (7.90-20.86) (11.04-19.70) (7.79-21.61) (8.14-21.41)
10-14 y 12.49 11.09 11.24 11.82 10.49 10.64 12.16 10.80 10.95
(9.25-16.65) (6.46-18.38) (6.77-18.19) (8.74-15.80) (6.09-17.46) (6.40-17.27) (9.00-16.23) (6.28-17.94) (6.59-17.75)
15-19 y 6.09 5.36 5.45 5.74 5.06 5.14 5.92 5.21 5.30
(4.44-8.30) (3.06-9.22) (3.22-9.12) (4.18-7.84) (2.88-8.71) (3.04-8.61) (4.31-8.08) (2.98-8.98) (3.13-8.87)
20-24 y 4.33 3.81 3.87 4.08 3.59 3.65 4.21 3.70 3.77
(3.10-6.03) (2.15-6.66) (2.27-6.58) (2.92-5.68) (2.02-6.28) (2.14-6.21) (3.01-5.86) (2.09-6.48) (2.20-6.40)
25-29 y 4.01 3.52 3.59 3.78 3.32 3.38 3.90 3.42 3.49
(2.85-5.62) (1.98-6.20) (2.10-6.11) (2.68-5.30) (1.86-5.84) (1.98-5.77) (2.77-5.47) (1.92-6.02) (2.04-5.95)
30-34 y 4.18 3.67 3.74 3.93 3.46 3.52 4.06 3.56 3.63
(2.96-5.86) (2.06-6.45) (2.19-6.36) (2.79-5.52) (1.94-6.08) (2.06-6.00) (2.88-5.70) (2.00-6.27) (2.13-6.19)
35-39 y 4.31 3.79 3.87 4.06 3.57 3.65 4.19 3.68 3.76
(3.05-6.05) (2.13-6.66) (2.28-6.56) (2.87-5.71) (2.00-6.28) (2.14-6.19) (2.97-5.89) (2.06-6.48) (2.21-6.38)
40-44 y 4.32 3.80 3.89 4.07 3.58 3.66 4.20 3.69 3.78
(3.06-6.08) (2.13-6.69) (2.30-6.58) (2.88-5.73) (2.01-6.31) (2.16-6.21) (2.97-5.91) (2.07-6.50) (2.23-6.40)
45-49 y 4.23 3.72 3.81 3.99 3.50 3.59 4.11 3.61 3.70
(2.99-5.96) (2.08-6.55) (2.25-6.44) (2.82-5.62) (1.96-6.18) (2.12-6.08) (2.91-5.79) (2.02-6.37) (2.18-6.26)
50-54 y 4.07 3.57 3.67 3.83 3.36 3.45 3.95 3.47 3.56
(2.87-5.72) (2.00-6.30) (2.17-6.18) (2.71-5.39) (1.88-5.94) (2.04-5.84) (2.79-5.56) (1.94-6.12) (2.10-6.01)
55-59 y 3.85 3.38 3.48 3.62 3.18 3.28 3.74 3.28 3.38
(2.72-5.41) (1.89-5.96) (2.07-5.84) (2.56-5.10) (1.78-5.62) (1.95-5.51) (2.64-5.26) (1.84-5.79) (2.01-5.68)
60-64 y 3.61 3.17 3.27 3.40 2.98 3.08 3.50 3.07 3.17
(2.55-5.08) (1.77-5.59) (1.96-5.47) (2.40-4.78) (1.67-5.27) (1.84-5.16) (2.47-4.93) (1.72-5.43) (1.90-5.31)
65-69 y 3.36 2.95 3.05 3.17 2.78 2.88 3.26 2.86 2.96
(2.37-4.74) (1.65-5.22) (1.83-5.10) (2.23-4.47) (1.55-4.92) (1.72-4.81) (2.30-4.60) (1.60-5.07) (1.77-4.95)
Overall
(5-69 y)
5.56 5.62 5.61 5.22 5.23 5.23 5.39 5.43 5.42
(4.01-7.65) (3.22-9.56) (3.35-9.26) (3.76-7.19) (3.00-8.93) (3.11-8.66) (3.89-7.42) (3.11-9.25) (3.23-8.97)
Ever asthma (%, 95% CI)
5-9 y 24.71 16.00 16.93 27.02 17.69 18.70 25.84 16.82 17.79
(20.28-29.73) (12.85-19.76) (13.64-20.82) (22.31-32.32) (14.26-21.74) (15.13-22.89) (21.27-30.99) (13.53-20.72) (14.36-21.82)
10-14 y 22.44 14.38 15.28 24.61 15.93 16.92 23.50 15.13 16.07
(18.32-27.17) (11.50-17.83) (12.26-18.88) (20.20-29.62) (12.79-19.67) (13.63-20.81) (19.24-28.37) (12.12-18.72) (12.92-19.81)
15-19 y 16.40 10.23 10.94 18.13 11.39 12.18 17.24 10.79 11.54
(13.21-20.19) (8.10-12.83) (8.69-13.68) (14.65-22.21) (9.04-14.24) (9.71-15.18) (13.91-21.18) (8.56-13.51) (9.18-14.41)
20-24 y 13.32 8.19 8.85 14.78 9.15 9.87 14.03 8.66 9.34
(10.65-16.54) (6.46-10.34) (6.99-11.13) (11.85-18.28) (7.23-11.51) (7.82-12.38) (11.23-17.38) (6.83-10.91) (7.39-11.74)
25-29 y 11.61 7.09 7.74 12.91 7.93 8.62 12.24 7.50 8.17
(9.25-14.49) (5.57-8.97) (6.10-9.77) (10.31-16.05) (6.24-10.01) (6.81-10.85) (9.76-15.24) (5.90-9.48) (6.45-10.29)
30-34 y 10.55 6.41 7.01 11.74 7.17 7.81 11.12 6.78 7.40
(8.38-13.20) (5.03-8.13) (5.52-8.87) (9.35-14.64) (5.64-9.07) (6.16-9.86) (8.84-13.89) (5.33-8.59) (5.83-9.35)
35-39 y 9.92 6.01 6.65 11.05 6.73 7.41 10.47 6.36 7.02
(7.87-12.44) (4.71-7.63) (5.23-8.42) (8.79-13.81) (5.29-8.53) (5.84-9.36) (8.31-13.10) (5.00-8.07) (5.53-8.88)
40-44 y 9.62 5.82 6.49 10.72 6.52 7.24 10.16 6.17 6.86
(7.62-12.07) (4.56-7.39) (5.11-8.22) (8.52-13.41) (5.12-8.26) (5.71-9.15) (8.06-12.72) (4.84-7.83) (5.40-8.68)
45-49 y 9.56 5.78 6.48 10.66 6.48 7.23 10.10 6.13 6.85
(7.58-12.00) (4.53-7.35) (5.09-8.21) (8.47-13.33) (5.09-8.22) (5.69-9.13) (8.02-12.66) (4.81-7.78) (5.39-8.67)
50-54 y 9.70 5.87 6.61 10.81 6.57 7.37 10.25 6.22 6.99
(7.69-12.16) (4.60-7.46) (5.20-8.37) (8.59-13.51) (5.16-8.33) (5.81-9.31) (8.13-12.83) (4.88-7.90) (5.50-8.84)
55-59 y 9.97 6.04 6.90 11.11 6.76 7.69 10.54 6.41 7.30
(7.91-12.50) (4.74-7.67) (5.43-8.72) (8.83-13.88) (5.31-8.57) (6.07-9.71) (8.37-13.19) (5.03-8.13) (5.75-9.22)
60-64 y 10.34 6.27 7.24 11.51 7.02 8.08 10.93 6.66 7.67
(8.21-12.94) (4.92-7.96) (5.71-9.15) (9.16-14.36) (5.52-8.89) (6.38-10.19) (8.69-13.67) (5.23-8.44) (6.05-9.68)
65-69 y 10.74 6.53 7.59 11.96 7.31 8.48 11.38 6.94 8.05
(8.54-13.44) (5.13-8.28) (5.98-9.57) (9.53-14.90) (5.75-9.25) (6.70-10.67) (9.06-14.20) (5.45-8.79) (6.36-10.15)
Overall
(5-69 y)
12.74 8.69 9.32 14.06 9.58 10.28 13.39 9.13 9.79
(10.21-15.77) (6.88-10.91) (7.40-11.67) (11.31-17.34) (7.61-11.99) (8.18-12.82) (10.75-16.54) (7.24-11.44) (7.79-12.24)
HIC – high-income country, LMIC – low- and middle-income country, CI – confidence interval
Table 1.
Continued
Song et al.
VIEWPOINTS
PAPERS
2022 • Vol. 12 • 04052 8www.jogh.org • doi: 10.7189/jogh.12.04052
The regional and national distribution of current wheezing and ever asthma in 2019
As shown in Figures 3-4 and detailed in Table S8 in the Online Supplementary Document, the SEAR had
the largest global cases of current wheezing (200.57million, 95% CI = 159.02-251.29) in 2019, while the EMR
had the least (65.91 million, 95% CI = 52.39-82.37). The age group that contributed the most cases of current
wheezing was 5-9 years in the AFR and EMR, 10-14 years in the AMR and SEAR, and 30-34 years in the EUR
and WPR. The overall prevalence of current wheezing in people aged 5-69 years was the highest in the AFR at
13.18% (95% CI = 10.47-16.47) and the lowest in the AMR at 10.03% (95% CI: 8.01-12.49). The ten coun-
tries with the most cases of current wheezing in descending order were China, India, United States of America,
Indonesia, Brazil, Pakistan, Nigeria, Bangladesh, Russian Federation, and Ethiopia, where the total cases were
439.2 million and accounted for more than half (58.2%) of the global cases of current wheezing in 2019 (see
Table S9 in the Online Supplementary Document).
Figure 3.
The age-specific prevalence (points) and number of cases (bar) of current wheezing or ever asthma in 2019, by
geographic region. AFR – African Region, AMR – Region of the Americas, SEAR – South-East Asia Region, EUR – Euro-
pean Region, EMR – Eastern Mediterranean Region, WPR – Western Pacific Region.
Figure 4.
The national prevalence of current wheezing or ever asthma in 2019.
For ever asthma, the WPR had the most cases (156.55 million, 95% CI = 124.2-196.14), whereas the EMR had
the smallest share (57.34 million, 95% CI = 45.59-71.65) in 2019. The age group that contributed the most
cases of ever asthma was 5-9 years across the six WHO regions. The estimated prevalence of ever asthma in
people aged 5-69 years was the highest in the AFR (11.31%, 95% CI = 8.99-14.12) and the lowest in the SEAR
(8.80%, 95% CI = 6.98-11.03). In 2019, more than half (56.4%, 363.6 million) of the global cases of ever asth-
ma were in ten countries, namely India, China, United States of America, Nigeria, Indonesia, Pakistan, Japan,
Brazil, Bangladesh, and Germany, in descending order.
Pooled ORs of associated factors of current wheezing and ever asthma across HICs and LMICs are shown in
Table S10 in the Online Supplementary Document and additional notes on associated factors are in Box 2.
Global, regional and naonal prevalence of asthma in 2019
VIEWPOINTS
PAPERS
www.jogh.org • doi: 10.7189/jogh.12.04052 9 2022 • Vol. 12 • 04052
DISCUSSION
To the best of our knowledge, this study provides the first comprehensive global, regional, and national analy-
sis of asthma based on four common epidemiological definitions before the COVID-19 pandemic. This study
offers a broad perspective on the disease necessary to inform clinical management, research priorities, inter-
vention focus, and health investments across world settings.
Asthma is generally prevalent among children and our findings are aligned with emerging reports that the
prevalence of asthma symptoms in young adults and through middle-aged is gradually increasing [11,12]. In
the 2021 GAN Phase I study (a follow-up to the ISAAC phase 3), the global prevalence of current wheezing
in 2017 was 9.9% among children aged 6-7 years and 11.0% among adolescents aged 13-14 years, while the
prevalence for ever asthma was 9.0% among the former and 11.0% among the latter, respectively [13]. Our
estimates of current wheezing in 2019 among 5-9 years (11.8%, 95% CI = 9.4-14.6) and 10-14 years (12.4%,
95% CI = 10.0-15.4) age groups are comparable with the reported GAN 1 prevalence rates among children and
adolescents, respectively. Although our estimates of ever asthma in both age groups were relatively higher, like-
ly explanations include 1) a global increase in population size of 5-year age cohorts over time, 2) improvement
of access to care worldwide, 3) improved medical care for respiratory conditions, 4) increased awareness and
diagnosis of wheeze, asthma and asthma-chronic obstructive pulmonary disease (COPD) syndrome, 5) chang-
es in environmental risk factors over time, and 6) the stochastic nature of global data on asthma prevalence.
Conducting long-term cohort studies among children is challenging, which makes studying trends in asthma
prevalence in children relatively difficult, limiting understanding of the global time trends [14]. With socio-de-
mographic changes and worsening exposure to risks over time, the prevalence and absolute number of cas-
es may be growing. Previous history of allergies and asthma in childhood persisting through adulthood may
have also translated to this increase in prevalence among young adults and the middle-aged [14]. It should be
noted that the possibility of asthma-COPD symptoms overlapping, or even the misdiagnosis of asthma with
advancing age, cannot be ruled out as a further source of variation in estimates. For example, the GBD collab-
orators used data from numerous sources to report that there were 358 million cases of asthma in 2015 [15]
and 339 million in 2016 [16]. However, a substantial reduction in global cases to 273 million in 2017 and 262
million in 2019 appears to be an important decreasing trend [1]. Some authors have raised concerns that the
large variations between the GBD estimates may be mainly due to changes in analytical methods rather than
contributions from new large-scale studies [17]. Furthermore, we opine that the GBD definition of asthma as
“reported diagnosis combined with wheezing in the past 12 months” may have excluded asthma cases with
stand-alone asthmatic symptoms, which in part explains why their estimates are lower than ours.
The geographic pattern of asthma prevalence observed in various ecological-economic analyses has consistent-
ly implied a higher prevalence in HICs compared to LMICs [18]. We also observed such disparity, especially
for current wheezing and ever asthma. We would expect that mild to moderate symptoms of asthma would
tend to be underdiagnosed across many LMICs. A relatively higher presence of poor housing conditions, with
over-crowding, damp environments, and second-hand smoking among children in many houses, would im-
ply a rising prevalence of asthma symptoms in LMICs. Moreover, severe symptoms and complications from
Our findings confirm an association of asthma symptoms with a personal or family history of atopy or allergies, includ-
ing allergic rhinitis and eczema. This would continue to be an important risk across HICs and LMICs and an important
consideration for clinical management. Although not specific to any settings in particular, reduced exposures to unhy-
gienic areas, commensals and non-pathogenic microbes in early life are believed to prompt low microbial diversity in the
respiratory tract – a likely factor for developing IgE-mediated immune response following exposures to airborne triggers
like grass pollens, animal dander, and fungal spores [20,21].
Tobacco smoking is a major risk factor for asthma across all age groups globally, one study observed [22]. While the
burden of asthma attributable to tobacco smoking may have been declining over the last three decades, it still accounts
for over 9% of the global disability-adjusted life years (DALYs) from asthma [22,23]. The high burden of asthma (15%
of global DALYs) reported in Europe over the years [24] has been thought to be smoking-related, particularly to sec-
ond-hand smoking, which is an important risk among women and children [23]. Although data gaps have limited the
understanding of the contribution of second-hand smoking to asthma burden across HICs and LMICs in recent studies,
it was estimated that there were about 40 000 asthma deaths due to second-hand smoking in 2004m with 28% occurring
in children and 47% in women [24]. Parental smoking is closely related, with estimates suggesting over 50% of exposed
children developing asthma symptoms, and this persisting up to the age of six for those exposed during pregnancy and/
or the first year of life [25] (additional notes on associated factors are in the Online Supplement Document, page 66).
Box 2.
Asthma risk factors
Song et al.
VIEWPOINTS
PAPERS
2022 • Vol. 12 • 04052 10 www.jogh.org • doi: 10.7189/jogh.12.04052
asthma appear to be more prominent in LMICs, especially among the elderly [18], possibly reflecting missed
diagnosis, under-treatment, and poorer overall response to the disease in these settings.
When exploring the specific regional variations in prevalence, current wheezing rates appear to be quite sim-
ilar across geographic regions except for the AFR (13.2%), ranging from 10.0% in the AMR to 11.6% in the
EUR. In addition, while we observed that the EUR (20.2%) and AMR (19.8%) returned the highest prevalence
of ever asthma mainly among children, the overall prevalence of ever asthma among persons aged 5-69 years
was still the highest in the AFR at 11.3%. The higher estimates of current wheezing and ever asthma in AFR
may be explained by several episodes of respiratory infections in many settings, which are often very severe
and poorly treated, resulting in repeated lung injuries that manifest in later life with breathing difficulties such
as asthma and other chronic respiratory conditions.
This study offers opportunities to better understand the epidemiology of a rather poorly researched disease in
many settings, and is complementary to the existing ISAAC studies [18], GBD reports [1], and recently, the
GAN estimation of asthma [13]. However, limitations are still present. First, the under- or over- estimation may
be an important limitation. The agreement between the definitions of asthma employed in some meta-analy-
ses was just above 60%, with many asthma cases fitting as controls [14]. Moreover, we acknowledge that the
older age group may be subject to recall bias for ever asthma, as persons may not recall having asthma in early
childhood, especially if the episodes were not severe. Differentiating asthma from other respiratory comorbid-
ities (like COPD) may lead to an overestimation of ever asthma in adults. Establishing national asthma preva-
lence estimates was also quite challenging; there is considerable uncertainty associated with our national-level
estimates, as data, particularly on associated factors, were not available from all countries and across different
age groups and sexes. We also acknowledge the limitations of applying the UNPD demographic data, which
is often questioned for its accuracy in LMICs.
The need to acquire standardised data over time from well-conducted studies across countries tops the list of
priorities towards improving the global, regional, and national estimates of asthma burden in the future [2].
Besides agreeing on definitions and protocols, standardised collation of hospital and administrative data across
different settings will help in assessing the impact of asthma on health care utilisation. The WHO recognised
the role of health care services in optimising asthma control by providing relevant information about disease
progression and treatment, including those related to professional advice, home monitoring of symptoms and
self-management [19]. It will also be important for LMIC health systems to invest more in primary care re-
spiratory services to meet the needs of this large segment of the population, especially for Africa and SEAR.
The contributions of environmental factors to asthma is poorly understood in many countries. Research on
various environmental factors, particularly air pollution in different contexts, could both explore genetic in-
teractions and assist our understanding of the determinants of asthma. Given its variable nature, diagnosing
asthma using lung function tests remains an issue in epidemiologic and clinical settings. It also highlights a
need to improve diagnostic skills across primary care settings, particularly in LMICs.
CONCLUSIONS
Asthma, based on whichever definition is used, was more common than previously estimated in the period
before the COVID-19 pandemic. Our study should be particularly useful for planning a national and sub-na-
tional response to asthma and will complement other international research efforts.
Funding: This research was supported by National Institute for Health Research (NIHR), Health Data Research UK.
Authorship contributions: DA, PS, IR, and AS designed study. DA, HS, JPRDS and PS extracted all data. DA, JPRDS, and
PS conducted data analyses. DA and PS wrote first draft with contributions from IR. IR, HC, and AS reviewed the final
draft and checked for important intellectual content. DA and PS verified the underlying data. DA, PS, AS, and IR had full
access to all the data in the study and had final responsibility for the decision to submit for publication.
Competing interests: IR is co-Editor-in-Chief of the Journal of Global Health. To ensure that any possible conflict of in-
terest relevant to the journal has been addressed, this article was reviewed according to best practice guidelines of inter-
national editorial organisations. The author completed the ICMJE Unified Competing Interest Form (available on request
from the corresponding author) and declare no competing interests.
Additional material
Online Supplementary Document
Global, regional and naonal prevalence of asthma in 2019
VIEWPOINTS
PAPERS
www.jogh.org • doi: 10.7189/jogh.12.04052 11 2022 • Vol. 12 • 04052
REFERENCES
1 Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 coun-
tries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204-
22. Medline:33069326 doi:10.1016/S0140-6736(20)30925-9
2 Global Asthma Network. The Global Asthma Report 2018. Available: http://globalasthmareport.org/resources/Global_Asth-
ma_Report_2018.pdf. Accessed: 28 April 2021.
3 Pearce N, Sunyer J, Cheng S, Chinn S, Bjorksten B, Burr M, et al. Comparison of asthma prevalence in the ISAAC and the
ECRHS. ISAAC Steering Committee and the European Community Respiratory Health Survey. International Study of Asthma
and Allergies in Childhood. Eur Respir J. 2000;16:420-6. Medline:11028654 doi:10.1183/9031936.00.16337700
4 Ellwood P, Asher MI, Beasley R, Clayton TO, Stewart AW, Committee IS. The international study of asthma and allergies in
childhood (ISAAC): phase three rationale and methods. Int J Tuberc Lung Dis. 2005;9:10-6. Medline:15675544
5 Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F, et al. International Study of Asthma and Allergies in Child-
hood (ISAAC): rationale and methods. Eur Respir J. 1995;8:483-91. Medline:7789502 doi:10.1183/09031936.95.08030483
6 Pearce N, Ait-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, et al. Worldwide trends in the prevalence of asthma symp-
toms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2007;62:758-66. Med-
line:17504817 doi:10.1136/thx.2006.070169
7 Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated
guideline for reporting systematic reviews. BMJ. 2021;372:n71. Medline:33782057
8 Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Socio-Demograph-
ic Index (SDI) 1950–2019. Available from: https://ghdx.healthdata.org/record/ihme-data/gbd-2019-socio-demographic-in-
dex-sdi-1950-2019. Accessed: 8 May 2021.
9 UN Department of Economic and Social Affairs Population Division. World Population Prospects 2019. Available from: https://
esa.un.org/unpd/wpp/. Accessed: 8 May 2021.
10 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. Medline:3802833 doi:10.1016/0197-
2456(86)90046-2
11 Hansen EF, Rappeport Y, Vestbo J, Lange P. Increase in prevalence and severity of asthma in young adults in Copenhagen. Tho-
rax. 2000;55:833-6. Medline:10992534 doi:10.1136/thorax.55.10.833
12 Withers AL, Green R. Transition for Adolescents and Young Adults With Asthma. Front Pediatr. 2019;7:301. Medline:31396495
doi:10.3389/fped.2019.00301
13 Asher MI, Rutter CE, Bissell K, Chiang C-Y, El Sony A, Ellwood E, et al. Worldwide trends in the burden of asthma symptoms
in school-aged children: Global Asthma Network Phase I cross-sectional study. Lancet. 2021;398:1569-80. Medline:34755626
doi:10.1016/S0140-6736(21)01450-1
14 Dharmage SC, Perret JL, Custovic A. Epidemiology of Asthma in Children and Adults. Front Pediatr. 2019;7:246. Med-
line:31275909 doi:10.3389/fped.2019.00246
15 GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjust-
ed life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic
analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5:691-706. Medline:28822787 doi:10.1016/
S2213-2600(17)30293-X
16 GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence,
and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global
Burden of Disease Study 2016. Lancet. 2017;390:1211-59. Medline:28919117 doi:10.1016/S0140-6736(17)32154-2
17 Asher MI, García-Marcos L, Pearce NE, Strachan DP. Trends in worldwide asthma prevalence. Eur Respir J. 2020;56:2002094.
Medline:32972987 doi:10.1183/13993003.02094-2020
18 Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S, et al. Global variation in the prevalence and severity of asthma symp-
toms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009;64:476-83. Med-
line:19237391 doi:10.1136/thx.2008.106609
19 Pearce G, Parke HL, Pinnock H, Epiphaniou E, Bourne CL, Sheikh A, et al. The PRISMS taxonomy of self-management support:
derivation of a novel taxonomy and initial testing of its utility. J Health Serv Res Policy. 2016;21:73-82. Medline:26377727
doi:10.1177/1355819615602725
20 Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989;299:1259-60. Medline:2513902 doi:10.1136/bmj.299.6710.1259
21 Rook GA, Martinelli R, Brunet LR. Innate immune responses to mycobacteria and the downregulation of atopic responses. Curr
Opin Allergy Clin Immunol. 2003;3:337-42. Medline:14501431 doi:10.1097/00130832-200310000-00003
22 Collaborators GBDT. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: a sys-
tematic analysis from the Global Burden of Disease Study 2015. Lancet. 2017;389:1885-906. Medline:28390697 doi:10.1016/
S0140-6736(17)30819-X
23 Mattiuzzi C, Lippi G. Estimation of Worldwide Burden of Smoking-Related Asthma. Int Arch Allergy Immunol. 2020;181:292-
5. Medline:31910429 doi:10.1159/000505024
24 Oberg M, Jaakkola MS, Woodward A, Peruga A, Pruss-Ustun A. Worldwide burden of disease from exposure to second-hand
smoke: a retrospective analysis of data from 192 countries. Lancet. 2011;377:139-46. Medline:21112082 doi:10.1016/S0140-
6736(10)61388-8
25 Strachan DP, Cook DG. Health effects of passive smoking. 6. Parental smoking and childhood asthma: longitudinal and case-con-
trol studies. Thorax. 1998;53:204-12. Medline:9659358 doi:10.1136/thx.53.3.204
